

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                         |
|-----------------------|-------------------------|
| <b>Name of entity</b> | <b>DigitalX Limited</b> |
| <b>ABN</b>            | <b>59 009 575 035</b>   |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                        |
|----------------------------|------------------------|
| <b>Name of Director</b>    | Peter Irwin Rubinstein |
| <b>Date of last notice</b> | 21 September 2018      |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Indirect  |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd and a beneficiary of BIOA Trust. |
| <b>Date of change</b>   | 10 December 2018  |

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|  |   |
|--|---|
| <b>No. of securities held prior to change</b>  | <p><b>Direct</b></p> <p>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p><b>Indirect</b></p> <p>13,266,296 Fully Paid Ordinary Shares<sup>1</sup></p> <p>3,000,000 Fully Paid Ordinary Shares<sup>2</sup></p> <p>7,000,000 Fully Paid Ordinary Shares<sup>3</sup></p> <p>3,400,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020<sup>1</sup></p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.</p> <p>2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.</p> <p>3. Held by ValueAdmin.Com Pty Ltd.</p> |
| <b>Class</b>   | <p>Unlisted Options exercisable at \$0.22 each on or before 10 December 2023.</p> <p>Unlisted Options exercisable at \$0.25 each on or before 10 December 2023.</p> <p>Unlisted Options exercisable at \$0.30 each on or before 10 December 2023.</p>   |
| <b>Number acquired</b>   | <p>1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023.</p> <p>1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023.</p> <p>2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023.</p>  |
| <b>Number disposed</b>   | Nil   |
| <p><b>Value/Consideration</b></p> <p>Note: If consideration is non-cash, provide details and estimated valuation</p> | <p>Nil cash consideration. Estimated total value of \$332,000, as detailed in the Notice of Meeting dated 3 October 2018.</p>   |

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |   |
|---|---|
| <b>No. of securities held after change</b>  | <p><b>Direct</b><br/>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p><b>Indirect</b><br/>13,266,296 Fully Paid Ordinary Shares<sup>1</sup></p> <p>3,000,000 Fully Paid Ordinary Shares<sup>2</sup></p> <p>7,000,000 Fully Paid Ordinary Shares<sup>3</sup></p> <p>3,400,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020<sup>1</sup></p> <p>1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023<sup>1</sup></p> <p>1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023<sup>1</sup></p> <p>2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023<sup>1</sup></p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.</p> <p>2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.</p> <p>3. Held by ValueAdmin.Com Pty Ltd.</p> |
| <p><b>Nature of change</b><br/>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>Issue of Unlisted Options as a long-term incentive, as approved by Shareholders on 22 November 2018.</p>   |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  |     |
| <b>Name of registered holder (if issued securities)</b>  |     |
| <b>Date of change</b>  |     |
| <p><b>No. and class of securities to which interest related prior to change</b><br/>Note: Details are only required for a contract in relation to which the interest has changed</p> |     |
| <b>Interest acquired</b>   |     |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|   |  |
|---|--|
| <b>Interest disposed</b>  |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small> |  |

**Part 3 – <sup>+</sup>Closed period**

|   |    |
|---|----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  |    |
| <b>If prior written clearance was provided, on what date was this provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                         |
|-----------------------|-------------------------|
| <b>Name of entity</b> | <b>DigitalX Limited</b> |
| <b>ABN</b>            | <b>59 009 575 035</b>   |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                      |
|----------------------------|----------------------|
| <b>Name of Director</b>    | Leigh Daniel Travers |
| <b>Date of last notice</b> | 5 July 2018          |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | N/A  |
| <b>Date of change</b>   | 10 December 2018   |
| <b>No. of securities held prior to change</b>   | <b>Direct</b><br>2,561,111 Fully Paid Ordinary Shares<br><br><b>Indirect</b><br>1,900,000 Fully Paid Ordinary Shares <sup>1</sup><br><br><sup>1</sup> Held by Leethal Pty Ltd, an entity associated with Mr Travers. |
| <b>Class</b>  | Performance Rights, subject to performance-based vesting conditions as detailed in the Notice of Meeting dated 3 October 2018, an expiring 10 December 2023.   |
| <b>Number acquired</b>  | 9,000,000  |
| <b>Number disposed</b>  | Nil  |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|   |  |
|---|--|
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | Nil cash consideration   |
| <b>No. of securities held after change</b>  | <b>Direct</b><br>2,561,111 Fully Paid Ordinary Shares<br><br>9,000,000 Performance Rights, subject to performance-based vesting conditions, an expiring 10 December 2023.<br><br><b>Indirect</b><br>1,900,000 Fully Paid Ordinary Shares <sup>1</sup><br><br><sup>1</sup> Held by Leethal Pty Ltd, an entity associated with Mr Travers. |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of Performance Rights, as approved by shareholders on 22 November 2018.  |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  |     |
| <b>Name of registered holder (if issued securities)</b>  |     |
| <b>Date of change</b>  |     |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |     |
| <b>Interest acquired</b>   |     |
| <b>Interest disposed</b>   |     |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |     |
| <b>Interest after change</b>   |     |

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

|   |    |
|---|----|
| Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   |    |
| If prior written clearance was provided, on what date was this provided?  |    |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                         |
|-----------------------|-------------------------|
| <b>Name of entity</b> | <b>DigitalX Limited</b> |
| <b>ABN</b>            | <b>59 009 575 035</b>   |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                   |
|----------------------------|-------------------|
| <b>Name of Director</b>    | Xue Samuel Lee    |
| <b>Date of last notice</b> | 18 September 2018 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Indirect   |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | The options are held by Blockchain Global Ltd, a Company in which Mr Lee is a Director.  |
| <b>Date of change</b>   | 10 December 2018   |
| <b>No. of securities held prior to change</b>   | 10,096,296 Fully Paid Ordinary Shares <sup>1</sup><br><br>1,203,704 Subscription Options exercisable at \$0.0324 each on or before 8 September 2020 <sup>1</sup><br><br>1,400,000 Convertible Note Options exercisable at \$0.0324 each on or before 8 September 2019 <sup>1</sup><br><br>2,800,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020 <sup>1</sup><br><br><div>1. Held by Mars Capital Australia Pty Ltd atf Mars Family Trust. Xue Samuel Lee the appointor of the Mars Family Trust.</div> |

+ See chapter 19 for defined terms.



**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |  |
|---|--|
| <b>Class</b>  | <p>Unlisted Options exercisable at \$0.22 each on or before 10 December 2023</p> <p>Unlisted Options exercisable at \$0.25 each on or before 10 December 2023</p> <p>Unlisted Options exercisable at \$0.30 each on or before 10 December 2023</p>   |
| <b>Number acquired</b>  | <p>1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023</p> <p>1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023</p> <p>2,000,000 Unlisted Options exercisable at \$0.30 each on or before 10 December 2023</p>   |
| <b>Number disposed</b>  | Nil  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | <p>Nil cash consideration. Estimated total value of \$332,000, as detailed in the Notice of Meeting dated 3 October 2018.</p>  |
| <b>No. of securities held after change</b>  | <p>10,096,296 Fully Paid Ordinary Shares<sup>1</sup></p> <p>1,203,704 Subscription Options exercisable at \$0.0324 each on or before 8 September 2020<sup>1</sup></p> <p>1,400,000 Convertible Note Options exercisable at \$0.0324 each on or before 8 September 2019<sup>1</sup></p> <p>2,800,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020<sup>1</sup></p> <p>1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023<sup>2</sup></p> <p>1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023<sup>2</sup></p> <p>2,000,000 Unlisted Options exercisable at \$0.30 each on or before 10 December 2023<sup>2</sup></p> <ol style="list-style-type: none"> <li>1. Held by Mars Capital Australia Pty Ltd atf Mars Family Trust. Xue Samuel Lee the appointor of the Mars Family Trust.</li> <li>2. Held by Blockchain Global Ltd, a Company in which Mr Lee is a Director.</li> </ol> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | <p>Issue of Unlisted Options as a long-term incentive, as approved by Shareholders on 22 November 2018.</p>  |

+ See chapter 19 for defined terms.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |     |
|---|-----|
| <b>Detail of contract</b>   | N/A |
| <b>Nature of interest</b>   |     |
| <b>Name of registered holder<br/>(if issued securities)</b>   |     |
| <b>Date of change</b>   |     |
| <b>No. and class of securities to which<br/>interest related prior to change</b><br><small>Note: Details are only required for a contract in<br/>relation to which the interest has changed</small> |     |
| <b>Interest acquired</b>  |     |
| <b>Interest disposed</b>  |     |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and<br/>an estimated valuation</small>   |     |
| <b>Interest after change</b>  |     |

## Part 3 – <sup>+</sup>Closed period

|   |    |
|---|----|
| <b>Were the interests in the securities or contracts detailed<br/>above traded during a <sup>+</sup>closed period where prior written<br/>clearance was required?</b> | No |
| <b>If so, was prior written clearance provided to allow the trade<br/>to proceed during this period?</b>  |    |
| <b>If prior written clearance was provided, on what date was this<br/>provided?</b>   |    |

---

<sup>+</sup> See chapter 19 for defined terms.